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B acterial meningitis caused by Streptococcus pneu-moniae has a high mortality rate and therefore 
requires appropriate and effective antimicrobial chemo-
therapy [1 , 2].  Vancomycin (VCM) is a recommended 
treatment.  However,  because VCM has a narrow ther-
apeutic window,  VCM dosing needs to be adjusted 
according to therapeutic drug monitoring (TDM) to 
maximize the therapeutic effect without toxicity,  par-
ticularly nephrotoxicity [3].  VCM trough levels of 
10-20 mg/L are recommended to improve the clinical 
outcome in methicillin-resistant Staphylococcus aureus 
(MRSA)-infected patients,  and levels of 15-20 mg/L are 
recommended for bacterial meningitis patients [3].  
VCM is excreted directly into urine,  mainly by glomer-
ular filtration,  and the most important factors that 
determine its dosage are renal function and body 
weight.  However,  VCM clearance (CLvcm) in critically 
ill patients is influenced by pathophysiological factors 
such as acute kidney injury (AKI) or augmented renal 
clearance (ARC) [4].  It is therefore necessary to estab-
lish a VCM-dosing regimen that utilizes novel renal 
functions,  because a standard indicator of glomerular 
filtration rate (GFR) such as creatinine clearance (CrCl) 
may not be accurate in critically ill patients [5].
Cystatin C provides a more precise GFR estimate 
compared to serum creatinine (SCr) [6].  Cystatin C is 
freely filtered through the glomerulus,  is almost com-
pletely reabsorbed and catabolized by proximal tubular 
cells,  and is an endogenous inhibitor of cysteine prote-
ases,  which are produced in all nucleated cells [7].  
Cystatin C-guided VCM dosing has been reported use-
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Cystatin C-guided vancomycin (VCM) dosing is useful in critically ill patients.  Its usefulness in septic patients 
with bacterial meningitis remains unknown,  as there are no published reports.  In this study,  we sought to clar-
ify its benefit.  Cystatin C was used to guide VCM dosing in a septic bacterial meningitis patient with normal 
kidney function,  according to therapeutic drug monitoring (TDM).  Using cystatin C,  the Bayesian meth-
od-based TDM made optimal VCM dosing possible,  and decreased the predicted error (4.85 mg/L) compared 
to serum creatinine (16.83 mg/L).  We concluded TDM of VCM using cystatin C can be considered in sepsis 
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ful in critically ill patients with various infections,  
including septic patients [8 , 9].  It was shown to 
enhance the GFR of critically ill patients with acute 
infectious meningitis [10].  The CLvcm of neurosurgical 
intensive care unit (ICU) patients was higher than that 
of non-ICU patients,  suggesting that it is influenced by 
meningitis in critically ill patients [11].  However,  the 
usefulness of cystatin C-guided VCM dosing in sepsis 
patients with bacterial meningitis remains unclear,  
because previous studies have excluded patients with 
high renal clearance,  and have not specified whether 
bacterial meningitis patients were included [8 , 9].  
Therefore,  it is necessary to examine the usefulness of 
cystatin C-guided VCM dosing for septic patients with 
bacterial meningitis,  because VCM concentration 
needs to be adjusted within a narrow therapeutic con-
centration window in such patients.  In this study,  we 
report a successful case of VCM dosing adjustment 
using cystatin C in a sepsis patient with bacterial men-
ingitis.
Case Report
This case was part of a study to examine the rela-
tionship between CLvcm and cystatin C in critically ill 
patients under the approval of the Tokushima 
University Hospital’s (Reference Number: 3285) Ethics 
Committee.  The patient was a 38-year-old man with 
neuromyelitis optica,  who was undergoing treatment 
with prednisolone 40 mg,  and was transferred to the 
intensive care unit (ICU) because of consciousness dis-
turbance.  His diagnosis was sepsis,  given that he had a 
sequential organ function assessment (SOFA) score of 8 
(Table 1),  coupled with acute infectious meningitis or 
suspected bacterial meningitis due to an increased cell 
count and protein level,  decreased cerebrospinal fluid 
(CSF),  and plasma glucose in CSF (Table 2).
At this point,  treatment with VCM and meropenem 
(the empiric therapy for penicillin-resistant Streptococcus 
pneumoniae,  the major cause of bacterial meningitis),  
and acyclovir (the empiric therapy for Herpes simplex 
virus) was commenced [1 , 2].  An SCr of 0.66 mg/dL 
and a urine output that did not reveal AKI indicated 
normal renal function (eGFR,  107.6 mL/min) [12].  
AKI was defined according to the KDIGO clinical prac-
tice guidelines: (1) an increase in serum creatinine level 
by ≥ 0.3 mg/dL; (2) an increase in serum creatinine 
level by ≥ 1.5 times baseline occurring within the prior 
7 days; or (3) urine volume < 0.5 ml/kg/h for 6 h [13].  
The patient’s mean urine output 6 h before VCM 
administration was 1.15 mL/kg/hr,  approximately 75% 
of normal urine output.  However,  his predicted eGFR 
was approximately 80 mL/min (107.6 × 0.75 = 80.7).  His 
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????? ?　 Baseline patient characteristics
Subject
Gender male
Height (cm) 174.1
Body weight (kg) 79.7
Age (years) 38
SCr (mg/dL) 0.66
Total bilirubin (mg/dL) 0.5
Serum albumin (g/dL) 2.6
White blood cell (×103/µL) 1.5
C- reactive protein (mg/dL) 3.56
Platelet (×104/µL) 389
SOFA score 8
APACHE II score 15
Renal parameters at 1st TDM (Day 5)
CrCl (CG formula) 250.9
CrCl (Hoek formula) 91.5
SCr,  serum creatinine; SOFA score,  sequential organ function 
assessment score; APACHE II score,  Acute Physiology and 
Chronic Health Evaluation II score; TDM,  therapeutic drug moni-
toring.
????? ?　 Information of cerebrospinal fluid and inflammation
CSF
Cell count
(/mL)
Polymorphonuclear cells
(%)
Glucose
(mg/dL) CSF/plasma glucose
Protein
(mg/dL)
CRP
(mg/dL)
Day1 28 13.3 67 0.33 134 3.56
Day2 37 10.9 63 0.41 120 12.37
Day8 13 2.6 83 0.29 75 6.08
Day15 11 3.1 128 0.51 67 1.55
CSF,  cerebrospinal fluid; CRP,  C-reaction protein.
initial VCM regimen of 1 g q12 h was decided based on 
his body weight (79.7 kg) and his estimated renal func-
tion (eGFR,  80.7 mL/min),  according to recommended 
therapeutic drug monitoring (TDM) guidelines 
(12.5 mg/kg).
Since his urine output was changing within short 
periods of time,  there was a concern of VCM overdose;  
therefore,  he did not receive a loading dose [14].  At the 
9th VCM dosing,  his first trough concentration was 
6.9 mg/L (Fig. 1),  and because his SCr (0.44 mg/dL) 
was lower than the standard value on day 5,  the assess-
ment of his renal function based on cystatin C showed 
that his VCM trough concentration was still below the 
desired therapeutic range (10-20 mg/L).  Using the 
pharmacokinetic (PPK) parameters of ICU patients 
documented by Revilla et al.,  the predicted VCM con-
centrations were calculated by applying the Bayesian 
method [15],  and because sepsis with bacterial menin-
gitis is a critical illness,  CrCl was calculated using the 
Hoek formula [16 , 17] as follows:
CrCl (mL/min)= −4.32+80.35/cystatin C×BSA/1.73m2
These calculations were performed using TDM soft-
ware (VCM-TDM Microsoft Excel,  version 3.0;  
Shionogi and Co.,  Osaka,  Japan).  The PPK parameters 
and patient characteristics reported by Revilla et al.,  
which included age,  sex,  body weight,  SCr 9 levels,  
and VCM dose,  were used because the predicted con-
centration of 17.25 mg/L was obtained using the 
Bayesian method when VCM (2 g q12 h) was adminis-
tered [15].  The second trough concentration at the 9th 
VCM dosing was found to be 22.1 mg/L with a predic-
tion error of 4.85 mg/L.  The formula used for calculat-
ing the prediction error is as follows (Table 3) [18]:
　　　　　
Owing to clinical and cerebrospinal fluid symptom 
improvements,  treatment with VCM was stopped on 
day 15,  and the cerebrospinal fluid culture remained 
negative.  Because of careful TDM using cystatin C,  
VCM-associated nephrotoxicity was not observed (SCr 
and urine output did not change during VCM treat-
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ment),  although VCM trough concentrations were 
almost 20 mg/L.  The cerebrospinal fluid culture 
revealed no positive findings for bacteria.
Discussion
Vancomycin (VCM)-dosing adjustment via thera-
peutic drug monitoring (TDM) with cystatin C is useful 
for achieving the desired therapeutic range in critically 
ill patients.  There are no reports on cystatin C-guided 
VCM dosing in septic patients with bacterial meningi-
tis,  even though it is necessary to accurately adjust 
VCM trough concentrations to fall within the recom-
mended therapeutic range.
The present study revealed that carrying out TDM 
using cystatin C made it possible to adjust the dose of 
VCM a in septic patient with bacterial meningitis.  The 
prediction errors obtained from the Bayesian method 
using the Cockcroft-Gault (CG) formula and the Hoek 
formula were then calculated and compared.  Previous 
reports revealed that in the Japanese population,  it is 
useful for a VCM-dosing regimen using cystatin C to 
utilize eGFR values derived from the Hoek formula 
[16 , 19 , 20].  Using the Hoek formula proposed by 
Kozono and a cystatin C value of 0.94 mg/L,  an esti-
mated CrCl value of 81.2 mL/min was obtained [17].  
We calculated the CrCl using the Hoek formula because 
eGFR using the Hoek formula does not differ when 
using CrCl [17 , 21].
CG formula: [22]
CrCl (mL/min)male = ((140 − age) × body weight)/
(72 × SCr (mg/dL))
CrCl (mL/min)female = CrCl (mL/min)male × 0.85
The prediction error obtained using the Hoek for-
mula was lower,  indicating higher prediction accuracy 
(Table 3).  Similarly,  the prediction error obtained from 
the Hoek formula (6.88 mg/L) calculated using other 
pharmacokinetic (PPK) parameters [23] was lower than 
that obtained from the CG formula (8.65 mg/L).  
Furthermore,  using the PPK parameters of hospitalized 
Japanese patients [20],  the prediction error using the 
Hoek formula was 6.94 mg/L.
We reported that the calculated pharmacokinetics of 
VCM utilizing the PPK parameters reported by Revilla 
et al.  [15] were similar to those calculated using the PPK 
parameters of Yasuhara et al.,  which have been used for 
calculated pharmacokinetics of VCM in patients with 
various infections,  including sepsis [24].  Previous 
reports have shown that the prediction errors in sepsis 
patients calculated using PPK parameters by Yasuhara et 
al.  are 4.28-6.41 (mg/L) [18 , 25].  The prediction error 
in this study,  4.85 (mg/L),  is plausible because it is 
similar to that of previous reports [18 , 25].  Therefore,  
the prediction accuracy was highest when the Hoek 
formula and the PPK parameters documented by Revilla 
et al.  were used [15].  This suggests that the prediction 
error may differ depending on the indicator used,  i.e.,  
GFR or PPK parameters.
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????? ?　 Prediction error by the Bayesian method using some population pharmacokinetics parameters
Population
Regression equation
CL
Regression equation
Vd
Residual variability
Predicted
concentration
(mg/L)
Prediction error
(mg/L)
Ref
ICU patients CL (mL/min/kg)= Vd (L/kg)=0.82×2.49A ±4. 2mg/L Hoek: 17.25 4.85 15
0.67×CrCl＋Age－0.24 A=0 or 1 if SCr ≤1 or SCr>1 CV (%)=9.8 CG: 5.27 16.83
ωCL=30.13 ωVd=22.83
ωCL (%)=16.4 ωVd (%)=38.8
MRSA-infected patients If CrCl <85 (mL/min) Vd (L)=60.71 CV (%)=23.7 Hoek: 15.22 6.88 23
CL=0.0487×CrCl (mL/min) ωVd (%)=25.4 CG: 13.45 8.65
If CrCl ≥85 (mL/min)
CL (L/hr)=3.51
ωCL (%)=38.5
Hospitalised patients CL (L/hr)= Vd (L/kg)=0.864 CV (%)=12.7 Hoek: 15.16 6.94 20
0.0525×GFR (mL/min) ωVd (%)=30.7
ωCL (%)=19.8
The residual variability of parameters was expressed as coefficient of variation (CV,  %).  The predicted concentrations were calculated using the 
Bayesian method,  using CrCl,  according to the Hoek formula or Cockcroft formula.  ICU,  intensive care unit; CL,  vancomycin clearance; Vd,  volume 
of distribution; Predicted conc,  predicted concentration; Ref,  Reference; SCr,  serum creatinine; ω,  between subject variability; CG,  Cockcroft-
Gault.
Previous studies showed that prednisolone increased 
serum cystatin C concentration [26].  In addition,  the 
accuracy of eGFRcys in patients taking prednisolone 
< 10 mg was lower than in patients taking ≥ 10 mg 
prednisolone [27].  However,  Kazama reported that 
steroids did not interfere with serum cystatin C concen-
tration [28].  Thus,  the influence of steroids on cystatin 
C is controversial.  Assessment using other markers in 
addition to cystatin C for renal function should be con-
sidered for dose adjustment of VCM using cystatin C 
taking steroids,  as in this case.
To conclude,  the TDM of VCM using cystatin C 
may be considered in bacterial meningitis sepsis 
patients with normal kidney function.  However,  given 
that this study is a case report of a single patient with 
normal renal function,  further studies are necessary to 
better clarify the usefulness of this method in treating a 
larger population of septic patients with bacterial men-
ingitis,  including those with abnormal renal function.
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